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In December 2019, an outbreak of a respiratory desease caused by a 
new coronavirus strain was detected in Wuhan, China. The disease 
spread rapidly around the world and was recognized as a pandemic 
by the World Health Organization in March 2020.
From the very beginning of the pandemic, society was faced 
with a scenario fraught with uncertainty: a new disease with 
severe effects on some patients and no specific treatment. The 
medical community reacted promptly and undertook the quest for 
treatment options, some based on prior experiences with diseases 
caused by other coronavirus strains or related viruses, and other 
approaches based on potential pathophysiological mechanisms 
- promising at the time - but without any supporting scientific 
evidence.
Thus, medications like hydroxychloroquine took center stage, 
bolstered by the opinions of  “renowned” scientists (1,2), but 
supported by poor-quality studies. Hope and haste showcased 
it as an effective therapy - despite many unanswered questions 
- unleashing demand for a medication of doubtful effectiveness 
and safety (3,4). The situation with hydroxychloroquine and 
other medications became even more convoluted when well-
known government leaders and politicians in Colombia and other 
parts of the world made statements regarding potential curative 
treatments for COVID-19 (chloroquine, ivermectin and fresh frozen 
plasma were the most frequently mentioned), triggering shortages 
and offering false hopes to their followers and supporters.
Showing that a treatment is really effective requires an 
impartial and unbiased assessment by means of a study known 
as a clinical trial, in which an experimental treatment is given to 
a group of randomly assigned patients and compared against the 
standard or control treatment, frequently against placebo. Ideally, 
this process must be blinded so that the researchers have no way of 
knowing what intervention the patients received, drug or placebo, 
and must have a follow-up period during which good and bad 
outcomes are assessed. Such a design allows to control for biases 
and to determine, with the greatest possible certainty, whether a 
medication is actually better or more efficacious than the control.
In order to avoid bias, clinical trials must meet the highest 
scientific standards. All treatments must be studied in clinical trials, 
regardless of their origin or their classification as conventional, 
complementary or alternative. Unverified theories, information 
based on personal experiences, years of experience using a 
treatment, reputation, optimism or wishful thinking are not enough 
to ensure the effectiveness and safety of any treatment. Without 
this painstaking process, useless or even harmful treatments 
might end up being prescribed merely on the grounds that  they 
are “thought or believed” to work (5). Needless to say, these studies 
are not the sole source of causality evidence and they are subject to 
bias, as is the case with other forms of scientific evidence (6).
It is our duty to demand that all available health care 
recommendations be based on sound scientific data, even if this is 
not always possible. Uncertainty in scientific thinking is inevitable, 
and providing completely sound recommendations in times of 
crisis is simply unfeasible (7). During a pandemic, a large proportion 
of the information is sketchy and comes from many different 
sources; it may elicit various interpretations, and striking a balance 
between acting on the basis of what is available or being cautious, 
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is a very difficult decision to make (8). In 
difficult times, it is even more important to 
abide by the principles of evidence based 
medicine as a strategy to improve the odds 
of obtaining the right answers to countless 
questions (9).
In critically ill patients with SARS-
CoV-2 infection, the development of acute 
respiratory distress syndrome occurs 
very quickly and is associated with high 
mortality. Given the unavailability of specific 
effective therapies, the recommendation is 
to implement supportive measures, that is 
to say, everything that is available in terms 
of intensive care developments, knowledge 
and technology.  In view of a scenario where 
there is no specific treatment for a very 
severe disease, the feeling of “failing to 
do anything to avoid death” has led to the 
“compassionate” use of treatments. In other 
words, acting out of despair to provide 
treatments that are not recommended 
or authorized and which could also be 
potentially dangerous besides being 
inadequate.
Any such intervention creates a false 
sense of reassurance, which is quite a 
serious problem. Tied to the use of those 
medications is the mistaken assumption 
that the probability of a beneficial effect 
is higher than the probability of causing 
harm, something which is far from real, 
considering the absence of clinical trials to 
support it (10). For example, if the patient 
dies after receiving the medication, the 
assumption is that the disease was the 
cause of death: “It was a very severe disease 
and the medication could not do much 
for the patient.”  If, on the other hand, 
the patient survives, the outcome will 
be attributed to the new medication. In 
fact, the cause of death may have been 
directly or indirectly associated with 
the medication in a patient who could 
have even had a chance of surviving on 
supportive treatment. Consequently, 
the assumption (disease-related death 
vs. drug-related survival) is flawed. As 
explained previously, it is impossible to 
determine whether a drug is useful or not 
without a control group of patients that 
have not received the intervention, i.e., 
without verification by means of a clinical 
trial (in epidemiology, this scenario is 
referred to as counterfactual). If a drug 
has not gone through this type of study 
to demonstrate safety and efficacy, it is 
reckless and potentially dangerous to 
recommended it for the treatment of any 
disease.
Moreover, compassionate use is 
fueled by the notion that no evidence will 
become available in the course of months, 
or even years. However, this is not true 
in the case of COVID-19, given that more 
than 1500 clinical trials are currently under 
way and registered in www.clinicaltrials.
gov, the most important database for the 
registration of these studies in the world. In 
other words, within weeks or months, more 
than 1500 studies will begin to provide 
results on the effectiveness and safety of 
several interventions. That means that 
evidence will soon be available on what 
works and what does not. The challenge - 
as evidence begins to emerge - lies in the 
ability to analyze, filter and interpret the 
information in order to gain insight into 
what is useful, how uncertain results are, 
and their applicability in different settings.
This is where systematic reviews of the 
literature play a critical role. For example, 
a physician who comes across a clinical 
trial that shows that drug A results in a 
slightly shorter length of stay and reaches a 
conclusion based only on that study, could 
assume that the result is an irrefutable 
truth. Only high-quality literature reviews 
and, more recently, living systematic 
reviews,  allow to summarize and synthesize 
all the available clinical trials, assess their 
quality, conduct a critical analysis and arrive 
at the most accurate conclusions possible 
for issuing treatment recommendations. 
Creating a detailed, clear and highly 
meaningful recommendation requires a 
complex, rigorous and systematic process 
to ensure its quality.
At the start of the pandemic, panic took 
over; overwhelmed by lack of evidence 
and despair many felt compelled to use 
medications with no support from the 
evidence. However, time has gone by and 
evidence has begun to emerge and will 
continue to do so for months to  come. 
We are now in a second stage of transition 
where we have learned about the virus and 
its mechanisms. Nonetheless, we need to 
be clear: there is no medication which, to 
this date, has been shown to be effective 
and safe in preventing contagion, treating 
mild forms or reducing complications.
Perhaps the sole exception so far is the 
use of steroids (dexamethasone) which, 
in critically ill patients, has been shown to 
reduce days on mechanical ventilation, and 
possibly mortality as well (11). It is important 
to highlight that its use is restricted to 
hospitalized patients under specific 
conditions; and several ongoing trials will 
help support, confirm or rule out this effect. 
Medications such as remdesivir have shown 
only a small effect over time until symptom 
resolution and require further research(12). 
To date, other drugs such as ivermectin, 
chloroquine, interferon, azithromycin, 
lopinavir/ritonavir, tocilizumab, or 
interventions such as convalescent plasma, 
lack consistent evidence supporting their 
use at any stage of the disease. Besides 
increasing healthcare costs, their use may 
expose patients to unnecessary risks.
We will soon enter a third phase, 
when the evidence of this huge number of 
ongoing studies will become available. By 
then, we might have been able to identify a 
treatment or ruled out the effectiveness of 
many. We still hope for a vaccine to prevent 
the disease, with sufficient scientific 
underpinning for large-scale use. Time will 
tell.
In short, determining the effectiveness 
and safety of a pharmacological treatment 
is no easy task, as it requires rigorous 
research mainly in the form of clinical 
trials. Moreover, when results are available, 
they need to be identified, assessed and 
summarized in order to arrive at valid 
and accurate conclusions by means of 
systematic reviews of the literature. It is 
only after evidence is summarized that 
credible and rigorous recommendations 
can be provided regarding the best and 
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safest treatments, following an explicit 
methodology. Then, and only then, will 
we be able to avoid the risk of creating 
false hopes, increasing healthcare costs 
unnecessarily or, what is even worse, 
recommending medications that could 
result in harm or even death.
These are difficult times, but our appeal 
is that we all act with caution, particularly as 
pertains to pharmacological interventions. 
Lack of evidence regarding the effectiveness 
of certain medications cannot be the 
rationale for the indiscriminate use of 
interventions of unknown effects.  Given 
the great number of ongoing studies, 
we will slowly gain access to more, and 
hopefully better, evidence to offer safer 
and more adequate treatments. We are 
now at the point where, for the good of 
our patients and of the health systems, no 
decision should be made without a critical 
analysis of the literature.  The words of 
Hippocrates are more relevant today than 
ever before:“primum non nocere”.
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